Given the above evidence, we then validated the anti-tumor effect of PI3K inhibitor copanlisib in different BCa models, and FGFR3 inhibitor infigratinib was used as a control since it is one of the only two FGFR3 inhibitors approved by the FDA for BCa treatment [25], which showed a better anti-tumor effect than the other one erdafitinib in our BCa cell lines as well as established organoid models (Supplementary Fig. S2A, B). Here, PIK3CA is linked to neoplasm.